OGA

Increasing O-GlcNAcylation Attenuates tau Hyperphosphorylation and Behavioral Impairment in rTg4510 Tauopathy Mice

17 views | Nov 12 2023

The study demonstrates that the OGA inhibitor Thiamet G increases O-GlcNAc levels, reduces hyperphosphorylated tau, and ameliorates hyperactivity in a mouse model of tauopathies, suggesting its potential as a therapeutic approach for Alzheimer's disease and related conditions. [Read the Full Post]

MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy

25 views | Oct 31 2023

MK-8719, a selective O-GlcNAcase inhibitor, shows promise in elevating O-GlcNAc levels, reducing pathologic tau, and mitigating brain atrophy, suggesting its potential as a therapeutic approach for Alzheimer's disease and other tauopathies. [Read the Full Post]